Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Talis Biomedical's Debt-to-EBITDA or its related term are showing as below:
TLIS's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.6 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Talis Biomedical Debt-to-EBITDA Related Terms
Talis Biomedical Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Talis Biomedical's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLIS vs BJDX, BBLG, VTAK: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Talis Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Talis Biomedical Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Talis Biomedical's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Talis Biomedical's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.
Talis Biomedical (TLIS) has a Debt-to-EBITDA of -0.50 as of Jun. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Talis Biomedical.
Is Talis Biomedical's Debt-to-EBITDA too high?
Talis Biomedical's current Debt-to-EBITDA is -0.50. Overall, Talis Biomedical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Talis Biomedical's Debt-to-EBITDA compare to BJDX and BBLG?
Talis Biomedical's Debt-to-EBITDA of -0.50 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Talis Biomedical. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Talis Biomedical's current Debt-to-EBITDA is -0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Talis Biomedical stock overvalued right now?
Talis Biomedical (TLIS) has a current Debt-to-EBITDA of -0.50. The current Debt-to-EBITDA is -0.50. Talis Biomedical's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Talis Biomedical (TLIS), the current Debt-to-EBITDA is -0.50 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.
28GF Score
Get the complete analysis for TLIS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLIS has been successfully added to your 
